Ivabradine Shortage: What Providers and Prescribers Need to Know in 2026

As a prescriber managing heart failure patients, you may have heard from patients or pharmacy staff that Ivabradine is difficult to find or that prior authorization processes are creating delays. This clinical overview covers the current availability landscape for Ivabradine in 2026, the most common barriers your patients face, and actionable strategies to help them maintain uninterrupted therapy.

Current Availability Status (2026)

As of 2026, Ivabradine (Corlanor, Amgen) is not listed on the FDA's official Drug Shortage Database. There is no declared manufacturing shortage. However, the medication presents unique access challenges that affect a subset of patients:

Distribution gap: Many community and retail pharmacies do not routinely stock Ivabradine due to its specialized indication and high brand-name cost. Patients may need to call multiple pharmacies or switch to mail-order or hospital-affiliated pharmacy dispensing.

Generic availability: FDA-approved generic Ivabradine tablets are available from select manufacturers but are not uniformly stocked across all pharmacy systems. Prescribing generically ("Ivabradine, DAW 0") will enable pharmacist substitution where generics are available and should be the default for most patients.

Insurance prior authorization: Prior authorization is required by most commercial and Medicare Part D plans. Failure to document clinical necessity precisely — including LVEF ≤35%, sinus rhythm, resting HR ≥70 bpm, and evidence of maximized beta-blocker therapy — is a common cause of initial PA denials.

Prescribing Pearls to Improve Access

1. Write for Generic Ivabradine Unless Brand Is Required

Prescribe "Ivabradine" rather than "Corlanor" to allow substitution of generic formulations. Generic Ivabradine tablets carry the same FDA-approved indication and bioequivalence as Corlanor. At retail, generic Ivabradine can be obtained for as little as $55-$150 per month with discount coupons, compared to $800+ per month for brand-name Corlanor.

2. Optimize Prior Authorization Documentation

Prior authorization denials are often due to incomplete documentation. For a successful PA submission, include:

HF phenotype: HFrEF with LVEF ≤35% (include most recent echocardiography date and LVEF value)

NYHA functional class (II-IV)

Current resting heart rate (≥70 bpm) — include documentation from office visit

Evidence of sinus rhythm (ECG or Holter documentation preferred)

Current beta-blocker dose and documentation that it represents the maximum tolerated dose; or documented contraindication/intolerance to beta-blockers

Current GDMT medications (RAAS inhibitor/ARNI, diuretics, MRA, SGLT2i)

Consider using standardized PA templates that your office staff can populate efficiently. Many EHR systems (Epic, Cerner) have built-in PA support tools that can pull relevant clinical data automatically.

3. Prepare Patients for the PA Timeline

At the time of prescribing, set expectations with patients that insurance approval may take 5-14 business days. Provide a short supply of samples if available, or have your staff begin the PA process the same day you write the prescription. If the PA is denied, initiate a peer-to-peer review promptly — cardiologist-to-medical-director calls have high success rates for well-documented cases.

4. Direct Patients to the Right Pharmacy Type

Not all pharmacies stock Ivabradine reliably. Pharmacies most likely to have it:

Hospital outpatient pharmacies: Especially those affiliated with cardiology or HF programs

Mail-order pharmacies: Express Scripts, OptumRx, CVS Caremark — especially for 90-day supplies

Large chain pharmacies: CVS, Walgreens, Walmart can order Ivabradine within 1-3 business days if not in stock. Advise patients to call ahead.

Therapeutic Decision-Making When Access Is Delayed

If a patient faces a delay of several days or more in obtaining Ivabradine, consider the following:

Short-term: If the patient has been stable on Ivabradine, a brief interruption of a few days is unlikely to cause acute decompensation, but should be avoided in higher-risk patients (NYHA III-IV, recent hospitalization). Provide samples if available.

Beta-blocker optimization: If the patient is not at maximum tolerated beta-blocker dose, consider uptitrating carvedilol or metoprolol succinate to target doses as a bridge.

Digoxin: Consider as a bridge for rate control in selected patients (sinus rhythm, renal function adequate for monitoring), though its narrow therapeutic index requires close monitoring.

Savings Programs to Communicate to Patients

Amgen Corlanor Savings Card: For commercially insured patients; reduces copay to as low as $10-$25/month. Not valid for Medicare/Medicaid. Enrollment at amgen.com/corlanor.

Amgen Safety Net Foundation: Free Corlanor for uninsured/underinsured patients at ≤300% FPL (~$46,800/year for an individual). Call 1-888-762-6436.

GoodRx / SingleCare coupons: Can reduce generic Ivabradine cash price to $55-$150/month at participating pharmacies. Useful for uninsured patients or those with high-deductible plans.

Helping Patients Locate Ivabradine at Pharmacies

Encourage patients to use medfinder, a service that calls pharmacies near the patient and identifies which ones can fill the prescription — saving patients the exhausting task of calling multiple pharmacies themselves. Results are texted directly to the patient. This is particularly valuable for older patients with heart failure who may have limited mobility and energy for pharmacy searching.

Summary: Provider Action Checklist

Prescribe generic Ivabradine (DAW 0) unless brand is specifically required

Include complete clinical documentation when submitting prior authorization

Initiate PA on the same day as prescribing; provide samples to bridge any approval gap

Direct patients to hospital pharmacy, mail-order, or large chain pharmacies that can order the drug

Enroll eligible patients in Amgen Savings Card or Safety Net Foundation

Recommend medfinder to help patients search for Ivabradine at local pharmacies

For a more detailed pharmacy navigation guide for providers, see How to Help Your Patients Find Ivabradine in Stock.